Heron Therapeutics Files 8-K on Shareholder Votes & Financials

TL;DR

HERON THERAPEUTICS (HRTX) filed an 8-K today covering shareholder votes and financials.

AI Summary

Heron Therapeutics, Inc. filed an 8-K on October 15, 2025, reporting on matters submitted to a vote of security holders and financial statements. The company, formerly known as AP Pharma Inc. and Advanced Polymer Systems Inc., is incorporated in Delaware and headquartered in San Diego, California.

Why It Matters

This filing indicates important corporate actions and financial reporting, which can influence investor decisions and provide insights into the company's operational status.

Risk Assessment

Risk Level: low — This is a routine filing reporting on corporate actions and financial statements, not indicating any immediate material adverse events.

Key Players & Entities

• Heron Therapeutics, Inc. (company) — Registrant
• AP Pharma Inc (company) — Former company name
• Advanced Polymer Systems Inc (company) — Former company name
• Delaware (jurisdiction) — State of incorporation
• October 15, 2025 (date) — Date of report

FAQ

Key Financial Figures

• $0.01 — ch registered Common Stock, par value $0.01 per share HRTX The Nasdaq Capital M

Filing Documents

• hrtx-20251015.htm (8-K) — 72KB
• 0001193125-25-240253.txt ( ) — 208KB
• hrtx-20251015.xsd (EX-101.SCH) — 50KB
• hrtx-20251015_htm.xml (XML) — 5KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. At the Special Stockholders' Meeting (the " Special Meeting ")of Heron Therapeutics, Inc. (the " Company ") held on October 13, 2025, the Company's stockholders voted on two proposals, including: (1) to approve, pursuant to Nasdaq Listing Rule 5635(d), the issuance of a number of shares of the Company's common stock, par value $0.01 per share (" Common Stock ") in connection with the conversion, at the option of the holder, of convertible senior unsecured promissory notes due 2031 held by several non-affiliated purchasers, which could, under certain circumstances that may occur in the future, exceed 19.99% of the number of shares of the Company's Common Stock issued and outstanding prior to such issuance; and (2) to approve, pursuant to Nasdaq Listing Rule 5635(d), the issuance of a number of shares of the Company's Common Stock in connection with the automatic conversion of the Company's Series A Convertible Preferred Stock, par value $0.01 per share (" Series A Convertible Preferred Stock ") held by several non-affiliated holders, which could, under certain circumstances that may occur in the future, exceed 19.99% of the number of shares of the Company's Common Stock issued and outstanding prior to such issuance. Only stockholders of record as of the close of business on September 11, 2025 (the " Record Date ") were entitled to vote at the Special Meeting. As of the Record Date, 183,314,409 shares of common stock of the Company were outstanding and entitled to vote at the Special Meeting. At the Special Meeting, 95,425,824 shares of common stock of the Company were represented in person and by proxy, constituting a quorum for the Special Meeting. The votes with respect to each of the two proposals voted on at the Special Meeting are set forth below: Proposal 1: The Company's stockholders approved, pursuant to Nasdaq Listing Rule 5635(d), the issuance of a number of shares of the Company's Commo

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 104 Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Heron Therapeutics, Inc. Date: October 15, 2025 /s/ Ira Duarte Ira Duarte Executive Vice President, Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR